Novavax, Inc. (NVAX)
| Market Cap | 555.61M |
| Revenue (ttm) | 983.71M |
| Net Income (ttm) | -545.06M |
| Shares Out | 139.95M |
| EPS (ttm) | -5.41 |
| PE Ratio | n/a |
| Forward PE | 1.78 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,900,400 |
| Open | 3.890 |
| Previous Close | 3.890 |
| Day's Range | 3.860 - 4.020 |
| 52-Week Range | 3.530 - 11.360 |
| Beta | 1.60 |
| Analysts | Strong Buy |
| Price Target | 17.00 (+328.21%) |
| Earnings Date | May 7, 2024 |
About NVAX
Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand n... [Read more]
Financial Performance
In 2023, Novavax's revenue was $983.71 million, a decrease of -50.36% compared to the previous year's $1.98 billion. Losses were -$545.06 million, -17.16% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for NVAX stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 328.21% from the latest price.
News
Levi & Korsinsky, LLP Notifies Shareholders of Novavax, Inc. (NVAX) an Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / April 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Novavax, Inc. (NASDAQ:NVAX). The settl...
Hedge fund Shah Capital recommends two new candidates for Novavax board
U.S.-based hedge fund Shah Capital on Monday recommended the appointment of two new independent directors to the Novavax board.
Novavax failed to capitalize on fears surrounding mRNA vaccines, activist investor says
Hedge fund Shah Capital on Monday called for an “urgent shake up” at the board of Novavax over claims its management has failed to capitalize on safety concerns surrounding mRNA vaccines to boost sale...
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
GAITHERSBURG, Md. , April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data ...
Novavax to Participate in TD Cowen's 44th Annual Health Care Conference
GAITHERSBURG, Md. , Feb. 29, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in TD...
Novavax Stock Sinks as Revenue Misses Estimates in ‘Transition Year'
Novavax posts a fourth-quarter loss of $1.44 a share on revenue of $291.3 million.
Novavax sees 2024 sales flat to lower, aims to pick up COVID vaccine market share
COVID-19 vaccine maker Novavax on Wednesday said it expects revenue this year to be flat or lower as it works to improve its commercial performance and pick up market share from much larger rivals, Pf...
Novavax misses quarterly estimates, but vaccine maker narrows losses as it slashes costs
Novavax narrowed its losses in the quarter compared to the same period a year ago, even as demand for Covid products continues to plummet worldwide.
Novavax Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Achieved revenues in Q4 2023 of $291 million and full year 2023 of $1.0 billion Accelerating progress toward expanding pipeline via Phase 3 COVID-19-Influenza Combination vaccine trial in second half...
Novavax stock surges after resolving Gavi vaccine dispute
Vaccine developer Novavax (NVAX) is seeing its stock skyrocket after resolving a dispute with the global nonprofit vaccine alliance Gavi. In an agreement, Novavax has refunded a large portion of Gavi'...
Novavax Stock Soars 25%. A Vaccine Purchase Settlement Is One Reason Why.
Novavax reaches a settlement related to an advance purchase agreement with Gavi.
Novavax to settle dispute over canceled Covid vaccine purchase agreement
The total amount Novavax will pay depends on whether Gavi decides to order more Covid shots from the cash-strapped company over the next five years.
Novavax settles dispute with international vaccine group Gavi
Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had creat...
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advan...
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024
GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth...
Novavax to cut 12% of global workforce
Vaccine maker Novavax said on Wednesday it will reduce its total global workforce by about 12% as part of its ongoing efforts to reduce costs.
Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate i...
Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan
Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-base...
Health Canada authorizes Novavax's updated COVID shot for Omicron
Novavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the Omicron subvariant XBB.1.5, in individuals aged 12 years and older.
Novavax's Updated COVID-19 Vaccine Now Authorized in Canada
Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc...
Covid vaccine rates in the U.S. are slumping — and it will be a challenge to boost them
The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.
WHO authorizes emergency use of Novavax's updated COVID vaccine
Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company ...
Novavax's stock pops after WHO grants its COVID-19 vaccine emergency-use listing
Novavax Inc.'s stock NVAX soared 4.6% early Tuesday, after the company said its protein-based COVID-19 vaccine had been granted emergency-use listing by the World Health Organization. The move means t...
Novavax's Updated Protein-based COVID-19 Vaccine Now an Option for All 194 Member States of the World Health Organization
GAITHERSBURG, Md. , Nov. 28, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 C...